Piper Sandler Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
Tweet Send to a Friend
Piper Sandler analyst Biren Amin reiterated an Overweight rating and $200.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
